Group items tagged

The NIEHS and partnering Institutes and Centers are establishing an infrastructure, the Human Health Exposure Analysis Resource (HHEAR) as a continuation of the Children's Health Exposure Analysis Resource (CHEAR). The goal of this consortium is to provide the research community access to laboratory and statistical analyses to add or expand the inclusion of environmental exposures in their research and to make that data publicly available as a means to improve our knowledge of the comprehensive effects of environmental exposures on human health throughout the life course. This FOA solicits the Data Center. The Data Center will provide intellectual and logistical support for the maintenance, integration, analysis, interpretation, curation, and reuse of data generated by HHEAR in support of extramural research projects. The Data Center will build and manage an exposure data repository and associated data science resources, including a public access Data Portal, a Data Submission and Review Portal, and an ontology and associated standardized data structure. In addition, the Data Center will provide statistical, analytical, and informatic support for HHEAR components and studies using the HHEAR infrastructure. The ultimate goal is maximizing potential use and impact of exposure data in human health studies.

The purpose of this funding opportunity announcement (FOA) is to invite applications for a broad range of research efforts in computational genomics, data science, statistics, and bioinformatics relevant to one or both of basic or clinical genomic science, and broadly applicable to human health and disease. This FOA supports fundamental genomics research developing innovative analytical methodologies and approaches, early stage development of tools and software, and refinement or hardening of software and tools of high value to the biomedical genomics community. Work supported under this FOA should be enabling for genomics and be generalizable or broadly applicable across diseases and biological systems. All applications should address how the methods would scale to address larger and larger data sets. Also listed under R21

The purpose of this Funding Opportunity Announcement (FOA) is to support the discovery of promising candidate biomarkers that will facilitate the development of non-opioid therapeutic options for the treatment of pain conditions. The goal of this FOA is to encourage a biomarker discovery process that will result in the development of pain biomarkers that can withstand rigorous clinical and analytical validation. It is hoped that an increased availability of rigorous biomarkers for pain will facilitate the discovery and development of transformational non-opioid therapeutics for pain.

The National Library of Medicine (NLM) supports innovative research and development in biomedical informatics and data science. The scope of NLM's interest in these research domains is broad, with emphasis on new methods and approaches to foster data driven discovery in the biomedical and clinical health sciences as well as domain-independent, reusable approaches to discovery, curation, analysis, organization and management of health-related digital objects. Biomedical informatics and data science draw upon many fields, including mathematics, statistics, information science, computer science and engineering, and social/behavioral sciences. Application domains include health care delivery, basic biomedical research, clinical and translational research, precision medicine, public health, biosurveillance, health information management in disasters, and similar areas. NLM defines biomedical informatics as the science of optimal representation, organization, management, integration and presentation of information relevant to human health and biology. NIH defines data science as the interdisciplinary field of inquiry in which quantitative and analytical approaches, processes, and systems are developed and used to extract knowledge and insights from increasingly large and/or complex sets of data.

The purpose of this funding opportunity announcement (FOA) is to invite applications for a broad range of research efforts in computational genomics, data science, statistics, and bioinformatics relevant to one or both of basic or clinical genomic science, and broadly applicable to human health and disease. This FOA supports fundamental genomics research developing innovative analytical methodologies and approaches, early stage development of tools and software, and refinement or hardening of software and tools of high value to the biomedical genomics community. Work supported under this FOA should be enabling for genomics and be generalizable or broadly applicable across diseases and biological systems. All proposals should address how the methods would scale to address larger and larger data sets.

The Science of Science & Innovation Policy (SciSIP) program supports research designed to advance the scientific basis of science and innovation policy. Research funded by the program thus develops, improves and expands models, analytical tools, data and metrics that can be applied in the science policy decision making process.

Multiple groups using a variety of analytical techniques have reported the presence of different species of aSyn in biofluids such as blood, cerebrospinal fluid (CSF), saliva, and tears. Results suggest that aSyn levels may be different in Parkinson's disease compared to healthy controls. Thus, aSyn quantification in accessible body fluids may serve as a biomarker of disease diagnosis, target engagement, pharmacodynamic response, or patient stratification. At the same time, analysis of total aSyn in CSF collected in the Parkinson's Progression Markers Initiative (PPMI) study did not change significantly over the course of a year, indicating that total aSyn may not be a progression marker of PD. One of the hallmarks of PD is aSyn aggregation, and therefore oligomeric aSyn may represent a more pathologically relevant disease species to serve as a biomarker.

The National Eye Institute (NEI) supports large-scale clinical vision research projects, including randomized clinical trials and epidemiologic studies. At the time of submission, applications requesting support for these activities are expected to provide detailed information regarding the study rationale, design, analytic techniques, protocols and procedures, facilities and environment, organizational structure, and collaborative arrangements. This information is best conveyed in a well-documented Manual of Procedures (MOP), the development of which represents a costly and time-consuming activity. This FOA is designed to facilitate activities central to the refinement of a study protocol and procedures and the development of a detailed MOP. The NEI Clinical Study Planning Grant may be used to support the development of a MOP, as well as to conduct preliminary studies to refine study procedures or document recruitment potential. The grant must not be used to generate data on the effects of a proposed intervention. This NEI FOA is applicable to both epidemiologic and clinical trial research studies.

The purpose of the FOA is to support unbiased proteomics analysis of matched longitudinal CSF and plasma samples from Accelerating Medicine Partnership in Parkinson's disease (AMP PD) cohorts using a data independent acquisition (DIA) mass spectrometry platform, with the ultimate goal of identifying PD biomarkers for diagnosis, prognosis and progression. Proteomics data generated through this initiative will be broadly shared with the research community through the AMP PD Knowledge Portal to enable additional analyses and data integration across the various datatypes available through AMP PD. A staged approach will be used to first identify and address pre-analytical variables and then incorporate that information into the optimal design for the analysis of 4500 CSF and plasma samples.

NHGRI invites applications for research developing comparative approaches that can be used to understand genome structure and function and the relationship between genomic features and phenotypes. This program supports studies that enable the use of a diverse array of species to advance our ability to understand basic biological processes related to human health and disease, as well as studies that develop novel analytical tools and resources for the comparative genomics research community.

The National Institute of Biomedical Imaging and Bioengineering (NIBIB) and VentureWell have come together to support and expand DEBUT, a competition that recognizes undergraduate excellence in biomedical design and innovation. DEBUT challenges teams of students in undergraduate biomedical education to solve real-world problems in healthcare. Prizes of up to $20,000 will be awarded. Strong DEBUT submissions will demonstrate a mastery of analytical and design skills and capabilities; the ability to manage the product development process; the ability to work effectively in teams; and technical communication skills. Submissions will be judged on the following criteria: Significance of the problem being addressed Impact of the proposed solution on potential users and clinical care Innovative design Working prototype Additional prizes will be awarded to entries that also demonstrate: Market potential and economic feasibility Patentability

The purpose of this NOFO is to provide funding and technical assistance for PEPFAR countries to establish HIV recent infection surveillance to detect recent infections, monitor trends in the HIV epidemic, identify hot spots associated with recent HIV transmission, and inform programmatic interventions to reach epidemic control. Point-of-care tests for recent infection distinguish between recent (HIV seroconversion in the last 6 months, on average) and non-recent HIV infection and provide results within minutes. These data may be linked to HIV case-based surveillance for ongoing epidemic monitoring and used by programs to provide enhanced counselling for immediate ART initiation, prioritize index testing, and intervene to prevent HIV transmission. This NOFO will require a multi-disciplinary team with expertise in surveillance, laboratory, prevention, HIV testing services, health informatics, data management, data analytics, and supply chain to support the planning, implementation, and impact evaluation of this PEPFAR priority activity.

The purpose of this initiative is to support Genomic Centers for Infectious Diseases (GCID) to promote broad use and expand the application of genomics technologies and computational analysis to understand infectious diseases, with an emphasis on pathogens, their interaction with the host and microbiome, and to aid in the development of novel genomics-based tools to diagnose, prevent and treat infectious diseases. The GCID will support innovative technology development in all aspects of genomics, including the use of synthetic and genome editing technologies as well as functional genomics to address basic, translational, and clinically relevant questions in host-pathogen interactions. The knowledge generated, including research data, analytical software tools, computational models, experimental protocols, and reagents, is expected to be widely disseminated to the scientific community through publicly accessible databases and reagent repositories.

The National Institute of Biomedical Imaging and Bioengineering (NIBIB) and VentureWell have come together to support and expand DEBUT, a competition that recognizes undergraduate excellence in biomedical design and innovation. DEBUT challenges teams of students in undergraduate biomedical education to solve real world problems in healthcare. Prizes of up to $20,000 will be awarded, with a total prize purse of $80,000. Strong DEBUT submissions will demonstrate a mastery of analytical and design skills and capabilities; the ability to manage the product development process; the ability to work effectively in teams; and technical communication skills. Submissions will be judged on the following criteria: Significance of the problem being addressed Impact of proposed solution on potential users and clinical care Innovative design Working prototype

The illicit sale of fentanyl, fentanyl analogues, and other synthetic drugs is incredibly profitable, and their high potency in small quantities presents a low risk to traffickers. To respond to this challenge, the U.S. government's understanding of the production, transit, and sale of these drugs and their precursor chemicals must continually increase. We will support a data analytics provider that can produce reliable information to inform our future capacity building programming efforts to combat transnational organized crime. The combination of technology and investigative research on transnational criminal organizations has various potential applications, such as building partner capacity by giving countries leads on various transnational criminal networks, identifying target cells before problems infiltrate neighboring areas, using network overviews for strategy information, and providing training on a limited basis.

Dr. Chockalingam Sivakumar and his study team at Global Mantra Innovation are seeking interested collaborators to provide SME support and site identification for a Disease Management Analytics platform on a retrospective observational study about Type-2 Diabetes Mellitus.

CBER seeks to support the application of novel technologies for advanced manufacturing of complex biologic products, and innovative analytical approaches to improve product manufacturing and quality through active research.

CBER seeks to support the application of novel technologies for advanced manufacturing of complex biologic products, and innovative analytical approaches to improve product manufacturing and quality through active research.

This Funding Opportunity Announcement (FOA) invites applications that seek to apply one or more innovative methodologies in communication research across the cancer control continuum, from prevention, early detection, diagnosis, treatment, and survivorship, to end of life. Applications to this FOA should utilize one or more of the following analytic approaches, methods, and data sources, including but not limited to social media data mining, Natural Language Processing (NLP) techniques, online social network analysis, crowdsourcing research tools (e.g., mTurk), online search data, Ecological Momentary Assessment, neuroscience and biobehavioral approaches to communication, and geographic information systems. Studies should assess outcomes related to cancer prevention and control (e.g., knowledge, attitudes, beliefs, perceived risk, decision making in screening and treatment, information inequalities, social support, shared decision making, persuasion, caregiving, behavioral intentions, preventive behaviors, and policy support, among others). This FOA utilizes the Exploratory/Developmental Grant (R21) mechanism, which supports investigation of novel scientific ideas or new model systems, tools, or technologies that have the potential for significant impact on biomedical or biobehavioral research.

The purpose of this Funding Opportunity Announcement (FOA) is to support rigorous clinical validation of a candidate biomarker using retrospective and/or prospective methods in a manner that is consistent with the purpose of the biomarker. This FOA assumes that: 1) a candidate biomarker has already been identified, 2) an analytical method has been developed and validated that is consistent with the purpose of the biomarker and 3) a working hypothesis regarding context of use is in place. The goal of this FOA is to facilitate the advancement of robust and reliable biomarkers of neurological disease for use in multi-site clinical trials and clinical practice.